BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 17470859)

  • 1. Phase II trial of infusional fluorouracil, leucovorin, mitomycin, and dipyridamole in locally advanced unresectable pancreatic adenocarcinoma: SWOG S9700.
    Isacoff WH; Bendetti JK; Barstis JJ; Jazieh AR; Macdonald JS; Philip PA
    J Clin Oncol; 2007 May; 25(13):1665-9. PubMed ID: 17470859
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of advanced adenocarcinomas of the exocrine pancreas and the gallbladder with 5-fluorouracil, high dose levofolinic acid and oral hydroxyurea on a weekly schedule. Results of a multicenter study of the Southern Italy Oncology Group (G.O.I.M.).
    Gebbia V; Majello E; Testa A; Pezzella G; Giuseppe S; Giotta F; Riccardi F; Fortunato S; Colucci G; Gebbia N
    Cancer; 1996 Sep; 78(6):1300-7. PubMed ID: 8826954
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemoradiotherapy in the treatment of regional pancreatic carcinoma: a phase II study.
    Al-Sukhun S; Zalupski MM; Ben-Josef E; Vaitkevicius VK; Philip PA; Soulen R; Weaver D; Adsay V; Heilbrun LK; Levin K; Forman JD; Shields AF
    Am J Clin Oncol; 2003 Dec; 26(6):543-9. PubMed ID: 14663369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [5-FU, folinic acid and cisplatin (LV5FU2-P) for unresectable pancreatic cancer].
    Taïeb J; Lecomte T; Ezenfis J; Artru P; Mitry E; Boige V; Clavero-Fabri MC; Vaillant JN; Rougier P; Ducreux M
    Gastroenterol Clin Biol; 2002; 26(6-7):605-9. PubMed ID: 12193860
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II trial of cyclophosphamide, leucovorin, 5-fluorouracil 24-hour infusion and tamoxifen in pancreatic cancer.
    Eckel F; Lersch C; Lippl F; Assmann G; Schulte-Frohlinde E
    J Exp Clin Cancer Res; 2000 Sep; 19(3):295-300. PubMed ID: 11144522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I/II trial of intraperitoneal 5-Fluorouracil with and without intravenous vasopressin in non-resectable pancreas cancer.
    Oman M; Lundqvist S; Gustavsson B; Hafström LO; Naredi P
    Cancer Chemother Pharmacol; 2005 Dec; 56(6):603-9. PubMed ID: 16047145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of unresectable, locally advanced pancreatic adenocarcinoma with combined radiochemotherapy with 5-fluorouracil, leucovorin and cisplatin.
    Kornek GV; Schratter-Sehn A; Marczell A; Depisch D; Karner J; Krauss G; Haider K; Kwasny W; Locker G; Scheithauer W
    Br J Cancer; 2000 Jan; 82(1):98-103. PubMed ID: 10638974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical experience with chronomodulated infusional 5-fluorouracil chemoradiotherapy for pancreatic adenocarcinoma.
    Keene KS; Rich TA; Penberthy DR; Shepard RC; Adams R; Jones RS
    Int J Radiat Oncol Biol Phys; 2005 May; 62(1):97-103. PubMed ID: 15850908
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II evaluation of continuous-infusion 5-fluorouracil, leucovorin, mitomycin-C, and oral dipyridamole in advanced measurable pancreatic cancer: a North Central Cancer Treatment Group Trial.
    Burch PA; Ghosh C; Schroeder G; Allmer C; Woodhouse CL; Goldberg RM; Addo F; Bernath AM; Tschetter LK; Windschitl HE; Cobau CD
    Am J Clin Oncol; 2000 Oct; 23(5):534-7. PubMed ID: 11039519
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oxaliplatin, 5-fluorouracil, and leucovorin as second-line treatment for advanced pancreatic cancer.
    Novarino A; Satolli MA; Chiappino I; Giacobino A; Bellone G; Rahimi F; Milanesi E; Bertetto O; Ciuffreda L
    Am J Clin Oncol; 2009 Feb; 32(1):44-8. PubMed ID: 19194124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FOLFOX-6 combination as the first-line treatment of locally advanced and/or metastatic pancreatic cancer.
    Ghosn M; Farhat F; Kattan J; Younes F; Moukadem W; Nasr F; Chahine G
    Am J Clin Oncol; 2007 Feb; 30(1):15-20. PubMed ID: 17278889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase III Southwest Oncology Group 9415/Intergroup 0153 randomized trial of fluorouracil, leucovorin, and levamisole versus fluorouracil continuous infusion and levamisole for adjuvant treatment of stage III and high-risk stage II colon cancer.
    Poplin EA; Benedetti JK; Estes NC; Haller DG; Mayer RJ; Goldberg RM; Weiss GR; Rivkin SE; Macdonald JS
    J Clin Oncol; 2005 Mar; 23(9):1819-25. PubMed ID: 15774775
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II trial of 5-fluorouracil, leucovorin, and carboplatin in patients with unresectable biliary tree carcinoma.
    Sanz-Altamira PM; Ferrante K; Jenkins RL; Lewis WD; Huberman MS; Stuart KE
    Cancer; 1998 Jun; 82(12):2321-5. PubMed ID: 9635523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized trial of 5-fluorouracil, leucovorin and cisplatin in advanced pancreatic cancer.
    Huguier M; Barrier A; Valinas R; Flahault A; Adloff M; Pezet D; Jaeck D; Millat B;
    Hepatogastroenterology; 2001; 48(39):875-8. PubMed ID: 11462946
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of 5-fluorouracil, doxorubicin, and mitomycin C for metastatic small bowel adenocarcinoma.
    Gibson MK; Holcroft CA; Kvols LK; Haller D
    Oncologist; 2005 Feb; 10(2):132-7. PubMed ID: 15709215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II study of irinotecan with bi-weekly, low-dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFIRI) as salvage therapy for patients with advanced or metastatic gastric cancer.
    Kim SG; Oh SY; Kwon HC; Lee S; Kim JH; Kim SH; Kim HJ
    Jpn J Clin Oncol; 2007 Oct; 37(10):744-9. PubMed ID: 17923456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of cisplatin combined with continuous 5-FU versus bolus 5-FU and leucovorin, in metastatic gastrointestinal cancer (FFCD 9404 randomised trial).
    Duffour J; Bouché O; Rougier P; Milan C; Bedenne L; Seitz JF; Buecher B; Legoux JL; Ducreux M; Vetter D; Raoul JL; François E; Ychou M
    Anticancer Res; 2006; 26(5B):3877-83. PubMed ID: 17094417
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resection of locally advanced pancreatic cancer after downstaging with continuous-infusion 5-fluorouracil, mitomycin-C, leucovorin, and dipyridamole.
    Todd KE; Gloor B; Lane JS; Isacoff WH; Reber HA
    J Gastrointest Surg; 1998; 2(2):159-66. PubMed ID: 9834413
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Weekly infusional high-dose fluorouracil (HD-FU), HD-FU plus folinic acid (HD-FU/FA), or HD-FU/FA plus biweekly cisplatin in advanced gastric cancer: randomized phase II trial 40953 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group and the Arbeitsgemeinschaft Internistische Onkologie.
    Lutz MP; Wilke H; Wagener DJ; Vanhoefer U; Jeziorski K; Hegewisch-Becker S; Balleisen L; Joossens E; Jansen RL; Debois M; Bethe U; Praet M; Wils J; Van Cutsem E; ;
    J Clin Oncol; 2007 Jun; 25(18):2580-5. PubMed ID: 17577037
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intra-arterial infusion chemotherapy with 5-fluorouracil and cisplatin in advanced pancreatic cancer: a feasibility study.
    Sasada T; Denno R; Tanaka T; Kanai M; Mizukami Y; Kohno S; Takabayashi A
    Am J Clin Oncol; 2008 Feb; 31(1):71-8. PubMed ID: 18376231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.